Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 6% Higher – Should You Buy?

Posted by Brenda Bartman on Jul 10th, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report)’s share price traded up 6% on Wednesday . The company traded as high as $24.75 and last traded at $24.63. Approximately 1,223,386 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 1,615,878 shares. The stock had previously closed at $23.24.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on SNDX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, June 24th. Barclays upped their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Friday, June 12th. Jefferies Financial Group reissued a “buy” rating and set a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. Finally, Mizuho reduced their target price on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.55.

Read Our Latest Report on SNDX

Syndax Pharmaceuticals Trading Down 5.4%

The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. The company has a market capitalization of $2.08 billion, a P/E ratio of -8.43 and a beta of 0.37. The business has a 50 day moving average price of $20.04 and a 200 day moving average price of $21.35.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The business had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same quarter last year, the firm earned ($0.98) EPS. Syndax Pharmaceuticals’s quarterly revenue was up 224.3% compared to the same quarter last year. Analysts anticipate that Syndax Pharmaceuticals, Inc. will post -1.65 EPS for the current year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total transaction of $784,770.00. Following the transaction, the chief executive officer directly owned 484,843 shares in the company, valued at approximately $11,752,594.32. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Nicholas A.J. Botwood sold 34,280 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.00, for a total value of $617,040.00. Following the completion of the transaction, the chief marketing officer directly owned 60,885 shares of the company’s stock, valued at approximately $1,095,930. The trade was a 36.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 105,914 shares of company stock valued at $2,120,789 in the last three months. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC increased its holdings in shares of Syndax Pharmaceuticals by 3.2% in the first quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock valued at $556,000 after purchasing an additional 730 shares during the last quarter. Pallas Capital Advisors LLC boosted its holdings in shares of Syndax Pharmaceuticals by 8.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 10,985 shares of the company’s stock worth $231,000 after acquiring an additional 875 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after acquiring an additional 893 shares during the period. Schroder Investment Management Group grew its position in shares of Syndax Pharmaceuticals by 1.0% in the third quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock valued at $1,920,000 after purchasing an additional 1,241 shares during the last quarter. Finally, Verition Fund Management LLC increased its stake in shares of Syndax Pharmaceuticals by 7.5% during the fourth quarter. Verition Fund Management LLC now owns 18,460 shares of the company’s stock worth $388,000 after purchasing an additional 1,281 shares during the period.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.